Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34 Stem Cell Selection Therapy
- Development stage
- Phase 2
- Lead developer
- Diane George
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34 Stem Cell Selection Therapy is an investigational cell-based biological therapy developed by Dr. Diane George at Columbia University Medical Center. The therapy involves the ex vivo processing of allogeneic peripheral blood stem cells from matched or partially matched family or unrelated adult donors using the CliniMACS PLUS system (Miltenyi Biotec). By selectively enriching for CD34+ hematopoietic stem cells and depleting T-cells (CD3+ cells), the procedure aims to facilitate successful engraftment and immune reconstitution in patients with non-malignant disorders while significantly reducing the risk of graft-versus-host disease (GVHD). It is primarily being evaluated in children, adolescents, and young adults with a wide range of conditions, including bone marrow failure syndromes, primary and acquired immunodeficiencies, histiocytic disorders, and hemoglobinopathies such as sickle cell disease and beta-thalassemia.
- Other names
- CD34+ Stem Cell SelectionCD34+ selectionT-cell depleted allogeneic peripheral blood stem cell transplant
Beyond the preview
Go deeper on CD34 Stem Cell Selection Therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34 Stem Cell Selection Therapy.